Is it time to re-think the use of etravirine in patients with available genotypic resistance test?
Infect Dis (Lond)
.
2019 Jun;51(6):452-455.
doi: 10.1080/23744235.2019.1569257.
Epub 2019 Apr 30.
Authors
Filippo Del Puente
1
,
Niccolo' Riccardi
1
,
Lucia Taramasso
1
2
,
Alberto Borghetti
3
,
Alessandro D'Avino
4
,
Sara Irene Bonelli
5
,
Andrea De Luca
6
,
Maurizio Zazzi
6
,
Antonio Di Biagio
7
Affiliations
1
a Clinic of Infectious Diseases, Policlinico San Martino Hospital, Department of Health Sciences (DISSAL) , University of Genoa , Genoa , Italy.
2
b Infectious Diseases Unit, Department of Internal Medicine , Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan , Italy.
3
c Istituto di Clinica delle Malattie Infettive , Università Cattolica del Sacro Cuore , Rome , Italy.
4
d Ospedale Generale "Cristo Re" , Rome , Italy.
5
e UO Malattie Infettive - Ospedale San Jacopo , Pistoia , Italy.
6
f Infectious Diseases Unit , AOU Senese , Siena , Italy ;
7
g Department of Internal Medicine , Clinic of Infectious Diseases, Policlinico San Martino Hospital , Genoa , Italy.
PMID:
31035844
DOI:
10.1080/23744235.2019.1569257
No abstract available
Publication types
Letter
Comment
MeSH terms
HIV
HIV Infections*
Humans
Nitriles
Pyridazines*
Pyrimidines
Sweden
Substances
Nitriles
Pyridazines
Pyrimidines
etravirine